4/16
01:19 pm
ucbjy
FcRn Inhibitor Market is Predicted to Grow Rapidly During the Study Period (2020–2034) | DelveInsight [Yahoo! Finance]
Low
Report
FcRn Inhibitor Market is Predicted to Grow Rapidly During the Study Period (2020–2034) | DelveInsight [Yahoo! Finance]
4/12
07:18 am
ucbjy
UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting [Yahoo! Finance]
Low
Report
UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting [Yahoo! Finance]
4/12
07:00 am
ucbjy
UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting
Low
Report
UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting
4/10
08:00 am
ucbjy
UCB Launches Make HStory, an Educational Campaign Offering Resources and Support for Those Living with Hidradenitis Suppurativa
Low
Report
UCB Launches Make HStory, an Educational Campaign Offering Resources and Support for Those Living with Hidradenitis Suppurativa
4/9
08:13 am
ucbjy
BioIVT to Host Symposium and Workshop in Brussels on Advanced In Vitro ADME Methodologies [Yahoo! Finance]
Low
Report
BioIVT to Host Symposium and Workshop in Brussels on Advanced In Vitro ADME Methodologies [Yahoo! Finance]
4/4
07:07 am
ucbjy
FDA Accepts Supplemental Biologics License Applications for BIMZELX® (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations [Yahoo! Finance]
Low
Report
FDA Accepts Supplemental Biologics License Applications for BIMZELX® (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations [Yahoo! Finance]
4/4
07:00 am
ucbjy
FDA Accepts Supplemental Biologics License Applications for BIMZELX® (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations
Low
Report
FDA Accepts Supplemental Biologics License Applications for BIMZELX® (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations
3/22
02:11 am
ucbjy
UCB Convening Notice to the General Meeting of the Shareholders 2024 [Yahoo! Finance]
Low
Report
UCB Convening Notice to the General Meeting of the Shareholders 2024 [Yahoo! Finance]
3/9
12:06 pm
ucbjy
First Presentation of Year 4 BIMZELX® (bimekizumab-bkzx) Data Showed Long-Term Maintenance of Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis [Yahoo! Finance]
Low
Report
First Presentation of Year 4 BIMZELX® (bimekizumab-bkzx) Data Showed Long-Term Maintenance of Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis [Yahoo! Finance]
3/9
12:00 pm
ucbjy
First Presentation of Year 4 BIMZELX® (bimekizumab-bkzx) Data Showed Long-Term Maintenance of Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis
Low
Report
First Presentation of Year 4 BIMZELX® (bimekizumab-bkzx) Data Showed Long-Term Maintenance of Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis
3/8
12:05 pm
ucbjy
BIMZELX® 48-Week Phase 3 Analyses in Moderate-to-Severe Hidradenitis Suppurativa Showed Sustained Improvements in Skin Pain and Draining Tunnel Count [Yahoo! Finance]
Low
Report
BIMZELX® 48-Week Phase 3 Analyses in Moderate-to-Severe Hidradenitis Suppurativa Showed Sustained Improvements in Skin Pain and Draining Tunnel Count [Yahoo! Finance]
3/8
12:00 pm
ucbjy
BIMZELX® 48-Week Phase 3 Analyses in Moderate-to-Severe Hidradenitis Suppurativa Showed Sustained Improvements in Skin Pain and Draining Tunnel Count
Low
Report
BIMZELX® 48-Week Phase 3 Analyses in Moderate-to-Severe Hidradenitis Suppurativa Showed Sustained Improvements in Skin Pain and Draining Tunnel Count
2/28
07:03 am
ucbjy
UCB on Growth Path for a Decade Plus
Medium
Report
UCB on Growth Path for a Decade Plus
2/7
10:23 am
ucbjy
Seizure Action Plan Awareness Week Set For February 12-19 [Yahoo! Finance]
Low
Report
Seizure Action Plan Awareness Week Set For February 12-19 [Yahoo! Finance]